Pandion Therapeutics Announces Appointment of Nancy Stagliano to Its Board of Directors

July 26, 2018 |

2 min read

Pandion Therapeutics, Inc. announced that Nancy Stagliano, PhD will be joining its board of directors as independent director.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Pandion Therapeutics, Inc., a biotechnology company developing novel therapeutics to treat autoimmune and inflammatory diseases and transplant rejection, today announced that Nancy Stagliano, PhD will be joining its board of directors as independent director. She has more than 20 years of experience in the industry building multiple successful biotechnology companies. Dr. Stagliano most recently served as the CEO of True North Therapeutics, where she led the company to its acquisition by Bioverativ, Inc. for $400M upfront and total potential value of up to $825M. Previously, she served as CEO of iPierian, which she led to a successful exit with Bristol-Myers Squibb with $175M upfront and potential total consideration of $725M. Prior to iPierian, Dr. Stagliano served as CEO and co-founder of CytomX Therapeutics. “Dr. Stagliano’s extensive experience and valuable insights will be critical as we make important decisions regarding the growth and direction of the company,” said Anthony J. Coyle, PhD, co-founder and CEO of Pandion Therapeutics.

Dr. Stagliano joins Dr. Coyle, Alan Crane, co-founder and Chairman of Pandion, of Polaris Partners, Carlo Rizzuto, PhD, of Versant Ventures, Mitchell Mutz, PhD, of Roche Venture Fund, and Vikas Goyal of SR One on Pandion’s board of directors. “We look forward to welcoming a true industry veteran to our board,” said Crane.

About Pandion Therapeutics

Pandion Therapeutics is a biotechnology company developing a pipeline of antibody therapeutics to achieve localized immunomodulation for autoimmune and inflammatory diseases and transplantation. The company’s proprietary technology platform enables the design of bispecific antibodies with targeting fragments that bind to specific tissues at the local site of inflammatory disease, coupled with effector molecules that modulate immune activity to restore immune homeostasis.

Pandion was founded in 2017 and closed a $58M Series A financing round in early 2018 with funding from a strong syndicate of investors. The company is headquartered in Cambridge, Massachusetts. Please visit www.pandiontx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180726005016/en/

Contacts

Pandion Therapeutics
Anthony Coyle
info@pandiontx.com

Source: Pandion Therapeutics

View this news release online at:
http://www.businesswire.com/news/home/20180726005016/en

People